title: Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females.
abstract: OBJECTIVE
  Although photodynamic therapy (PDT) is an established treatment for choroidal neovascularization (CNV), the mechanisms are still not completely elucidated. Damage to the retinal pigment epithelium (RPE) was observed following uncomplicated PDT in young patients.
  
  
  METHODS
  Observational case series.
  
  
  METHODS
  Four female patients between the age of 26 and 39 years presented with visual loss because of classic CNV. In two 39 years old females the CNV originated secondary to a small chorioretinal scar, in a 26 and a 36-year-old woman the CNV was of idiopathic cause. All patients received standard PDT according to the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study protocol.
  
  
  RESULTS
  One to three months after an uncomplicated PDT with verteporfin, severe pigment epithelial alterations in the treatment area were observed. The neovascular membranes responded favorably to the treatment and demonstrated fibrosis and resolution of leakage. Ophthalmoscopically and angiographically, atrophy of the retinal pigment epithelium was seen precisely delineating the size of the treatment spot used. Vision declined in two patients from 0.3 to 0.1 and 0.15 to 0.1. The two other patients demonstrated an increase of visual acuity from 0.7 to 0.9 and from 0.4 to 0.9. The retinal pigment epithelium alterations did not resolve during follow-up, but remained unchanged in area and intensity.
  
  
  CONCLUSIONS
  Characteristic retinal pigment epithelium alterations were observed in young female patients with small classic CNV following PDT. Unusual retinal pigment epithelium damage in young female patients without any associated disease might be related to a possible inherent defect in the RPE or to the hormonal status of this specific patient population.
authors.affiliation: Ophthalmology Department, Chu Brugmann and Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium. Laurence.postelmans@chu-brugmann.be
authors.forename: Laurence
authors.initials: L
authors.lastname: Postelmans
authors.forename: Brigitte
authors.initials: B
authors.lastname: Pasteels
authors.forename: Pascale
authors.initials: P
authors.lastname: Coquelet
authors.forename: Hind
authors.initials: H
authors.lastname: El Ouardighi
authors.forename: Claire
authors.initials: C
authors.lastname: Verougstraete
authors.forename: Ursula
authors.initials: U
authors.lastname: Schmidt-Erfurth
mesh_terms: D000328:Adult; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D005260:Female; D005355:Fibrosis; D005451:Fluorescein Angiography; D006801:Humans; D010778:Photochemotherapy / Q000009:adverse effects*; D017319:Photosensitizing Agents / Q000009:adverse effects* / Q000627:therapeutic use; D010857:Pigment Epithelium of Eye / Q000187:drug effects* / Q000473:pathology; D011166:Porphyrins / Q000009:adverse effects* / Q000627:therapeutic use; D012164:Retinal Diseases / Q000139:chemically induced* / Q000175:diagnosis; D000077362:Verteporfin; D014792:Visual Acuity
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin